THOUSAND OAKS, Calif., May 17, 2005 (BUSINESS WIRE) -- Amgen Inc. (NASDAQ:AMGN), the world´s largest
biotechnology company, today announced the appointment of Jim Daly to
the new position of senior vice president, North America Commercial
Operations. Daly, formerly vice president and general manager of the
U.S. Oncology Business Unit at Amgen, will be responsible for leading
the company´s commercial activities in the United States and Canada.
Daly will report to George Morrow, executive vice president, Global
"The newly formed North America Commercial Operations
organization, with Jim at the head, will provide better coordination
and integration across Amgen´s United States and Canada commercial
operations as we prepare to launch new therapies emerging from our
product pipeline," said Morrow. "Jim brings 20 years of extensive
sales, marketing and general management leadership experience to this
new position and I anticipate great success for this important part of
our business under Jim´s guidance."
Daly joined Amgen in early 2002 as vice president and general
manager, U.S. Oncology Business Unit. In this role, Daly led the
successful launches of Aranesp(R) (darbepoetin alfa), Neulasta(R)
(pegfilgrastim) and Kepivance(TM) (palifermin), and was instrumental
in establishing their strong market positions. Prior to joining Amgen,
Daly spent 17 years at Glaxo Wellcome/GlaxoSmithKline (GSK), where he
progressed through positions of increasing responsibility in
marketing, including his role as vice president and general manager,
Respiratory and Anti-Infectives Business Division at GSK.
Daly received his undergraduate degree in Pharmacy and his
master´s degree in Business Administration from the State University
of New York in Buffalo.
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology.
Amgen, Thousand Oaks
Christine Cassiano, 805-447-4587 (media)
Arvind Sood, 805-447-1060 (investors)